Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ALLO stock hub

Allogene Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ALLOis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

784.3M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ALLO

In the news

Latest news · ALLO

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-53.4

P25 -105.6P50 -46.5P75 -3.1

ROIC-29.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ALLO market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

188

Groups with data

Currency

USD

Showing 188 of 188 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001737287
Company name	Allogene Therapeutics, Inc.
Country	United States
Country code	US
Cusip	019770106
Employees	152
Employees Change	-77%
Employees Change Percent	-33.62
Enterprise value	$617.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2018-10-11
Isin	US0197701065
Last refreshed	2026-05-10
Market cap	$784.3M
Market cap category	Small-Cap
Price	$2.28
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	ALLO
Website	https://allogene.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-24.34%
EV Sales Forward	64,111.07x
FCF yield	-19.08%
P/B ratio	1.79x
PS Forward	81,450.4x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross Profit	$-150.2M
Net Income	$-190.9M
Net Income Growth Quarters	5%
Net Income Growth Years	3%
Profit Per Employee	$-1.3M
ROA	-26.82
Roa5y	-22.63
ROCE	-53.97
ROE	-53.42
Roe5y	-45.06
ROIC	-29.11

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	90.08%
Cagr3y	-29.83%
Cagr5y	-40.29%
EPS Growth Quarters	10
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$415.9M
Cash	$250.2M
Current Assets	$257.7M
Current Liabilities	$32.5M
Debt	$83.3M
Debt Equity	$0.28
Equity	$292.5M
Interest Coverage	-192.5
Liabilities	$123.4M
Long Term Assets	$158.2M
Long Term Liabilities	$90.8M
Net Cash	$167M
Net Cash By Market Cap	$21.29
Net Cash Growth	-17.23%
Net Debt Equity	$-0.57
Tangible Book Value	$292.5M
Tangible Book Value Per Share	$1.28
WACC	6.23

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	7.93
Net Working Capital	$-16.8M
Quick ratio	7.74
Working Capital	$225.2M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-13.25%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	90%
200-day SMA	1.64
3Y total return	-65.45%
50-day SMA	2.4
50-day SMA vs 200-day SMA	50over200
5Y total return	-92.41%
All Time High	55
All Time High Change	-95.85%
All Time High Date	2020-05-26
All Time Low	0.86
All Time Low Change	164.47%
All Time Low Date	2025-05-14
ATR	0.21
Beta	0.46
Beta1y	1.48
Beta2y	1.62
Ch YTD	66.42
High	2.36
High52	4.46
High52 Date	2026-04-13
High52ch	-48.88%
Low	2.25
Low52	0.86
Low52 Date	2025-05-14
Low52ch	164.47%
Ma50ch	-5.04%
Premarket Change Percent	-0.44
Premarket Price	$2.26
Premarket Volume	60,917
Price vs 200-day SMA	39.28%
RSI	48.76
RSI Monthly	45.12
RSI Weekly	56.26
Sharpe ratio	1.12x
Sortino ratio	1.81
Total Return	-13.25%
Tr YTD	66.42
Tr1m	-12.98%
Tr1w	6.05%
Tr3m	34.91%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	15
Analyst Count Top	2
Analyst Price Target Top	$10.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.18
Earnings Revenue Estimate	1,820x
Operating Income	$-206.9M
Price target	$8.35
Price Target Change	$266
Price Target Change Top	$361

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	268,701,373%
Float Percent	78.12%
Shares Insiders	4.57%
Shares Institutions	36.67%
Shares Out	343,977,920
Shares Qo Q	1.8%
Shares Yo Y	13.25%
Short Float	13.54%
Short Ratio	2.51
Short Shares	10.58

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-187.3M
Average Volume	17,387,546.75x
Bv Per Share	1.28
CAPEX	$-386,000
Ch1m	-12.98
Ch1w	6.05
Ch1y	90
Ch3m	34.91
Ch3y	-65.45
Ch5y	-92.41
Ch6m	93.22
Change	0.44%
Change From Open	-0.44
Close	2.27
Days Gap	0.88
Depreciation Amortization	12,359,000
Dollar Volume	10,205,995.9
Earnings Date	2026-05-13
Earnings Time	amc
EBIT	$-206.9M
EBITDA	$-194.6M
EPS	$-0.87
F Score	1
FCF	$-149.6M
FCF EV Yield	-24.24x
FCF Per Share	$-0.44
Financing CF	30,157,000
Fiscal Year End	December
Founded	2,017
Investing CF	95,559,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-12
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-03-12
Ma150	1.79
Ma150ch	27.16%
Ma20	2.31
Ma20ch	-1.26%
Net CF	-23,530,000
Next Earnings Date	2026-05-13
Open	2.29
Optionable	Yes
Position In Range	27.27
Post Close	2.28
Postmarket Change Percent	-0.44
Postmarket Price	$2.27
Ppne	112,727,000
Pre Close	2.27
Price Date	2026-05-08
Ptbv Ratio	2.68
Relative Volume	0.26x
Share Based Comp	37,642,000
Tr6m	93.22%
Us State	California
Volume	4,476,314

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ALLO pay a dividend?

Capital-return profile for this ticker.

Performance

ALLO stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ALLO?

Insider, institutional, and short-interest positioning.

Institutional ownership

+36.7%

Float: +78.1% of shares outstanding

Insider ownership

+4.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ALLO momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

48.8

Neutral momentum band

Price vs 200-day MA

+39.3%

50/200-day relationship not available

Beta (5Y)

0.46

Less volatile than the market

Sharpe ratio

1.12

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ALLO

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ALLO stock rating?

Allogene Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ALLO analysis?

The full report lives at /stocks/ALLO/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ALLO?

The latest report frames ALLO around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ALLO page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.